{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05585320",
            "orgStudyIdInfo": {
                "id": "IMM1104-101"
            },
            "organization": {
                "fullName": "Immuneering Corporation",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors",
            "officialTitle": "A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants With Previously Treated RAS-Mutated Advanced or Metastatic Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-phase-study-of-imm-in-participants-with-previously-treated-ras-mutant-advanced-or-metastatic-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-10-31",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-10-14",
            "studyFirstSubmitQcDate": "2022-10-14",
            "studyFirstPostDateStruct": {
                "date": "2022-10-18",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-28",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-01",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Immuneering Corporation",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 dose (RP2D) of IMM-1-104 to further explore the anti-tumor activity of IMM-1-104 as monotherapy and in combination with approved agents in multiple Phase 2a proof-of-concept cohorts in malignancies of interest."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumor",
                "Pancreatic Adenocarcinoma",
                "Malignant Melanoma (Cutaneous)",
                "Non-small Cell Lung Cancer (NSCLC)"
            ],
            "keywords": [
                "pan-RAS",
                "KRAS",
                "NRAS",
                "HRAS",
                "Targeted therapy",
                "Metastatic cancer",
                "Advanced cancer",
                "RAS",
                "Adenocarcinoma",
                "MEK",
                "Dual MEK",
                "MEK 1/2",
                "Mitogen-Activated Protein Kinase (MAPK)",
                "G12A",
                "G12C",
                "G12D",
                "G12F",
                "G12R",
                "G12S",
                "G12V",
                "G13C",
                "G13D",
                "G13R",
                "Q61H",
                "Q61K",
                "Q61L",
                "Q61R",
                "A146T",
                "A146V",
                "K117N"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 210,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "IMM-1-104 monotherapy (Treatment Group A)",
                    "type": "EXPERIMENTAL",
                    "description": "IMM-1-104 monotherapy for first/second line pancreatic adenocarcinoma; first/second/third line melanoma; or second/third line non small cell lung cancer",
                    "interventionNames": [
                        "Drug: IMM-1-104 Monotherapy (Treatment Group A)"
                    ]
                },
                {
                    "label": "IMM-1-104 in combination with mGnP (Treatment Group B)",
                    "type": "EXPERIMENTAL",
                    "description": "IMM-1-104 in combination with modified gemcitabine and nab-paclitaxel (mGnP) for first line pancreatic adenocarcinoma",
                    "interventionNames": [
                        "Drug: IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)"
                    ]
                },
                {
                    "label": "IMM-1-104 in combination with mFFX (Treatment Group C)",
                    "type": "EXPERIMENTAL",
                    "description": "IMM-1-104 in combination with modified FOLFIRINOX (mFFX) for first line pancreatic adenocarcinoma",
                    "interventionNames": [
                        "Drug: IMM-1-104 + modified FOLFIRINOX (Treatment Group C)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "IMM-1-104 Monotherapy (Treatment Group A)",
                    "description": "Once-daily, oral IMM-1-104 dose administered in 28-day cycles until treatment discontinuation criteria are met",
                    "armGroupLabels": [
                        "IMM-1-104 monotherapy (Treatment Group A)"
                    ],
                    "otherNames": [
                        "IMM-1-104"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)",
                    "description": "Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of gemcitabine and nab-paclitaxel until treatment discontinuation criteria are met.\n\nGemcitabine will be administered at a dose of 1000 mg/m\\^2 nab-Paclitaxel will be administered at a dose of 125 mg/m\\^2",
                    "armGroupLabels": [
                        "IMM-1-104 in combination with mGnP (Treatment Group B)"
                    ],
                    "otherNames": [
                        "IMM-1-104 + mGnP"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "IMM-1-104 + modified FOLFIRINOX (Treatment Group C)",
                    "description": "Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of modified FOLFIRNOX until treatment discontinuation criteria are met.\n\nFOLFIRINOX will be administered as follows:\n\nFolinic Acid will be administered at 400 mg/m\\^2 Fluorouracil will be administered at 2400 mg/m\\^2 Irinotecan will be administered at 150 mg/m\\^2 Oxaliplatin will be administered at 85 mg/m\\^2",
                    "armGroupLabels": [
                        "IMM-1-104 in combination with mFFX (Treatment Group C)"
                    ],
                    "otherNames": [
                        "IMM-1-104 + mFFX"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Phase 1: Adverse Events",
                    "description": "Number of participants with adverse events",
                    "timeFrame": "From treatment initiation through 30 days following the last IMM-1-104 dose"
                },
                {
                    "measure": "Phase 1: Dose-Limiting Toxicities",
                    "description": "Number of participants with dose-limiting toxicities",
                    "timeFrame": "The first 21 days of study treatment"
                },
                {
                    "measure": "Phase 1: Recommended Phase 2 Dose (RP2D) candidate",
                    "description": "Selection of candidate RP2D to take forward into Ph2a",
                    "timeFrame": "Initiation of study treatment through 21 days (up to approximately 18 months)"
                },
                {
                    "measure": "Phase 2a: Overall Response Rate",
                    "description": "The proportion of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR), based on RECIST 1.1 criteria",
                    "timeFrame": "After up to 48 weeks (12 cycles) of study treatment"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Phase 1/2a: Maximum Observed Plasma Concentration of IMM-1-104",
                    "description": "Cmax",
                    "timeFrame": "After 12 weeks (3 Cycles) of study treatment"
                },
                {
                    "measure": "Phase 1/2a: Time to Reach Maximum Plasma Concentration of IMM-1-104",
                    "description": "Tmax",
                    "timeFrame": "After 12 weeks (3 Cycles) of study treatment"
                },
                {
                    "measure": "Phase 1/2a: Area Under Plasma Concentration (AUC) Time Curve of IMM-1-104",
                    "description": "AUC0-t",
                    "timeFrame": "After 12 weeks (3 Cycles) of study treatment"
                },
                {
                    "measure": "Phase 2a: Disease Control Rate (DCR)",
                    "description": "The proportion of participants who have a best overall response (BOR) of stable disease (SD) or better",
                    "timeFrame": "After 16 weeks (4 Cycles) of study treatment"
                },
                {
                    "measure": "Phase 2a: Progression Free Survival (PFS)",
                    "description": "The time interval between study treatment start and disease progression or death due to any cause.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Phase 2a: Duration of Response (DOR)",
                    "description": "The time interval between an assessment of partial response (PR) or better and disease progression or death due to any cause.",
                    "timeFrame": "Up to approximately 2 years."
                },
                {
                    "measure": "Phase 2a: Landmark 3-Month Survival",
                    "description": "The proportion of participants who are still alive after three months on study.",
                    "timeFrame": "After 3 months of study participation."
                },
                {
                    "measure": "Phase 2a: Landmark 6-Month Survival",
                    "description": "The proportion of participants who are still alive after six months on study.",
                    "timeFrame": "After 6 months of study participation."
                },
                {
                    "measure": "Phase 2a: Overall Survival (OS)",
                    "description": "The time interval between study treatment start and death due to any cause.",
                    "timeFrame": "Up to approximately 2 Years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Must be \u226518 years of age\n* Must have histologically or cytologically confirmed diagnosis as follows:\n\n  1. Monotherapy Phase 1: A locally advanced unresectable or metastatic solid tumor malignancy that harbors a RAS (KRAS, NRAS, or HRAS) activating mutation.\n  2. Monotherapy Phase 2a: A locally advanced unresectable or metastatic solid tumor malignancies: pancreatic ductal adenocarcinoma (PDAC), RAS-mutant melanoma, or RAS-mutant non-small cell lung cancer (NSCLC)\n  3. Combination therapy (both phases): A locally advanced unresectable or metastatic PDAC\n* Participants must be treatment naive or received prior systemic standard-of-care treatment as follows:\n\n  1. Monotherapy Phase 1: received at least 1 line of systemic standard-of-care treatment for their advanced or metastatic disease\n  2. Monotherapy Phase 2a:\n\n     1. First-line PDAC participants will have received no previous systemic anti-cancer therapy. Second-line PDAC participants will have received no more than one prior systemic anti-cancer therapy.\n     2. First-line melanoma participants will have received no previous systemic anti-cancer therapy. Second- and third-line participants will have received and failed one or two prior systemic anti-cancer therapies, respectively.\n     3. NSCLC participants will have received at least one and no more than two previous lines of systemic therapy.\n  3. Combination therapy (both phases): PDAC participants will have received no previous systemic anti-cancer therapy for their advanced or metastatic disease.\n* Must have evidence of measurable disease (at least one target lesion) per RECIST v1.1 criteria\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate organ function\n\nExclusion Criteria:\n\n* Inability to swallow oral medications\n* Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases\n* History or concurrent evidence of retinal vein occlusion (RVO) or current risk factors for RVO. History of serous retinopathy, retinal edema, or retinal pigment epithelial detachment (RPED)\n* Impaired cardiovascular function or clinically significant cardiac disease\n* History of rhabdomyolysis within 3 months prior to start of study treatment\n* Active skin disorder requiring systemic treatment within 3 months prior to the start of study treatment\n* Females who are pregnant, breastfeeding, or planning to become pregnant and males who plan to father a child while enrolled in this study.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "IMM1104-101 Study Team",
                    "role": "CONTACT",
                    "phone": "(860) 321-1302",
                    "email": "clinicaltrials@immuneering.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Vinny Hayreh, MD",
                    "affiliation": "Immuneering Corporation",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "City of Hope",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Vincent Chung, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "University of California San Diego",
                    "status": "RECRUITING",
                    "city": "San Diego",
                    "state": "California",
                    "zip": "92037",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Peter Vu, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.71533,
                        "lon": -117.15726
                    }
                },
                {
                    "facility": "Sarcoma Oncology Center",
                    "status": "RECRUITING",
                    "city": "Santa Monica",
                    "state": "California",
                    "zip": "90403",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sant Chawla, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.01945,
                        "lon": -118.49119
                    }
                },
                {
                    "facility": "Sarah Cannon Research Institute",
                    "status": "RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80218",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jason Henry, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "Florida Cancer Specialists and Research Institute",
                    "status": "RECRUITING",
                    "city": "Lake Mary",
                    "state": "Florida",
                    "zip": "32746",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alexander Philipovskiy, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.75888,
                        "lon": -81.31784
                    }
                },
                {
                    "facility": "Northwestern University",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60611",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sunandana Chandra, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "Dana Farber Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Elizabeth Buchbinder, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Hematology Oncology Associates of Central New York",
                    "status": "RECRUITING",
                    "city": "East Syracuse",
                    "state": "New York",
                    "zip": "13057",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Steven Duffy, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.06534,
                        "lon": -76.07853
                    }
                },
                {
                    "facility": "Weill Cornell Medicine",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10021",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Anna Pavlick, DO",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Duke University Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27710",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jeffrey Clarke, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                },
                {
                    "facility": "SCRI Oncology Partners",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "27203",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Melissa Johnson, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Shubham Pant, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "NEXT Oncology",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "NEXT Oncology",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alex Spira, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                },
                {
                    "facility": "University of Wisconsin Clinical Science Center",
                    "status": "RECRUITING",
                    "city": "Madison",
                    "state": "Wisconsin",
                    "zip": "53792",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Vincent Ma, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.07305,
                        "lon": -89.40123
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008545",
                    "term": "Melanoma"
                },
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000018358",
                    "term": "Neuroendocrine Tumors"
                },
                {
                    "id": "D000017599",
                    "term": "Neuroectodermal Tumors"
                },
                {
                    "id": "D000009373",
                    "term": "Neoplasms, Germ Cell and Embryonal"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009380",
                    "term": "Neoplasms, Nerve Tissue"
                },
                {
                    "id": "D000018326",
                    "term": "Nevi and Melanomas"
                },
                {
                    "id": "D000012878",
                    "term": "Skin Neoplasms"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "asFound": "Adenocarcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "relevance": "LOW"
                },
                {
                    "id": "M11528",
                    "name": "Melanoma",
                    "asFound": "Malignant Melanoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20495",
                    "name": "Neuroendocrine Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M19845",
                    "name": "Neuroectodermal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20388",
                    "name": "Neuroectodermal Tumors, Primitive",
                    "relevance": "LOW"
                },
                {
                    "id": "M12318",
                    "name": "Neoplasms, Germ Cell and Embryonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M12325",
                    "name": "Neoplasms, Nerve Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "M12448",
                    "name": "Nevus, Pigmented",
                    "relevance": "LOW"
                },
                {
                    "id": "M12446",
                    "name": "Nevus",
                    "relevance": "LOW"
                },
                {
                    "id": "M20470",
                    "name": "Nevi and Melanomas",
                    "relevance": "LOW"
                },
                {
                    "id": "M15681",
                    "name": "Skin Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "T4091",
                    "name": "Neuroendocrine Tumor",
                    "relevance": "LOW"
                },
                {
                    "id": "T4092",
                    "name": "Neuroepithelioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000017239",
                    "term": "Paclitaxel"
                },
                {
                    "id": "D000093542",
                    "term": "Gemcitabine"
                },
                {
                    "id": "C000627770",
                    "term": "Folfirinox"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000972",
                    "term": "Antineoplastic Agents, Phytogenic"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000050257",
                    "term": "Tubulin Modulators"
                },
                {
                    "id": "D000050256",
                    "term": "Antimitotic Agents"
                },
                {
                    "id": "D000050258",
                    "term": "Mitosis Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1671",
                    "name": "Irinotecan",
                    "relevance": "LOW"
                },
                {
                    "id": "M19537",
                    "name": "Paclitaxel",
                    "asFound": "Sessions",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2985",
                    "name": "Gemcitabine",
                    "asFound": "Mg/kg",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1674",
                    "name": "Oxaliplatin",
                    "relevance": "LOW"
                },
                {
                    "id": "M8600",
                    "name": "Fluorouracil",
                    "relevance": "LOW"
                },
                {
                    "id": "M231",
                    "name": "Albumin-Bound Paclitaxel",
                    "relevance": "LOW"
                },
                {
                    "id": "M271136",
                    "name": "Folfirinox",
                    "asFound": "High Resolution",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8618",
                    "name": "Folic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "M6191",
                    "name": "Leucovorin",
                    "relevance": "LOW"
                },
                {
                    "id": "M29233",
                    "name": "Levoleucovorin",
                    "relevance": "LOW"
                },
                {
                    "id": "M11900",
                    "name": "Mitogens",
                    "relevance": "LOW"
                },
                {
                    "id": "M26197",
                    "name": "Tubulin Modulators",
                    "relevance": "LOW"
                },
                {
                    "id": "M26196",
                    "name": "Antimitotic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "T446",
                    "name": "Folic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "T447",
                    "name": "Folinic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "T448",
                    "name": "Folate",
                    "relevance": "LOW"
                },
                {
                    "id": "T475",
                    "name": "Vitamin B9",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Micro",
                    "name": "Micronutrients"
                },
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                },
                {
                    "abbrev": "Vi",
                    "name": "Vitamins"
                }
            ]
        }
    },
    "hasResults": false
}